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Abstract 
As a directive of the Hospital Engagement Network 2.0 and in order to improve patient care, CHS 
NorthEast undertook project to improve glycemic control, specifically to reduce overall incidence of 
hypoglycemia and hyperglycemia. The primary overall goal was reduction of incidence of hyperglycemia 
via utilization of pharmacist or pharmacy extender chart review. In addition to this, incidence of 
hypoglycemia was also tracked to ensure the percent of patients experiencing hypoglycemia remained 
low. The project took place in three main phases, the baseline data collection and proposal phase, the 
student TheraDoc intervention phase, and the interdisciplinary rounds phase. Over the course of one 
year, glycemic control was improved in the targeted units within the hospital. The student phase 
showed modest improvements, while the interdisciplinary rounds phase demonstrated a more dramatic 
improvement.  
 
Introduction 
The ADA guidelines recommend the use of an insulin regimen including basal, nutritional and correction 
components for patients with diabetes who are admitted to the hospital.1 Quite often the regimen does 
not include all three components. Some barriers to this may include number of insulin administrations, 
simplification of orders, uncertainty related to patient’s home diabetes medications, and fear of 
hypoglycemia. Despite the fear of severe adverse effects due to hypoglycemia, a well-structured insulin 
protocol can mitigate the risk of this occurring. Hyperglycemia is associated with a number of negative 
outcomes such as increased inpatient complications, ventilator days, ICU and hospital length-of-stay, 
and an overall increased cost.2 
Carolinas HealthCare System (CHS) was part of a group of 17 hospital systems called the Hospital 
Engagement Network 2.0 (HEN) to take part in a grant program funded by the Centers for Medicare and 
Medicaid Services that sought to reduce all-cause preventable harm to patients. One goal of this 
program that CHS established was to reduce all out-of-range point-of-care (POC) blood glucose 
measurements by 40% from baseline. The range was defined as any value < 70mg/dL and >179 mg/dL. 
This goal was assigned to all hospitals within CHS, including CHS NorthEast, a 457 bed hospital in 
Concord, NC. A baseline period was measured in 2015 and found the total percentage of out-of-range 
values at NorthEast to be ~38%. The 40% reduction goal was calculated to be ~22.7% by the end of the 
HEN 2.0 trial period, October 2016. A previous intervention was effective in reducing incidence of 
hypoglycemia. Because of this, and the fear of severe negative outcomes associated with hypoglycemia, 
there was some push-back among providers against the idea of initiating more aggressive therapy for 
hyperglycemia. 
The project was mainly driven by the pharmacy department. Other stakeholders included the diabetes 
educators, physicians and nurses. Various committees throughout the hospital and healthcare system 
were aware of the goal and the attached grant.  
 
 
 
Methods 
An initial assessment of baseline data was conducted for the months November 2015-January 2016. The 
goal was to identify possible problem areas and potential target areas for intervention. The assessment 
phase lasted from January to March 2016. In April the results were presented to the various 
shareholders including physicians, pharmacists, nurses, hospital administrators and diabetes educators. 
There were three specific presentations given to the NorthEast Diabetes Care Team, at the April 
Carolinas Hospitalist Group (CHG) monthly meeting, and finally to the Performance 
Improvement/Patient Safety Committee meeting, which included the CMO. After each presentation, 
feedback was gathered and potential interventions were modified accordingly. Following this period, 
the specific final interventions were defined.  
The first would be a three-month trial period of student monitoring of glycemic control in one particular 
15 bed general medicine unit called “Med 1.” May 2016, the first month, was a pilot phase that was 
used to train 4th year pharmacy students and identify complications and confounders. June and July 
2016 were the months of the live student intervention phase. Students were trained to use TheraDoc, a 
clinical surveillance software. TheraDoc was and is used by CHS pharmacists in the Antimicrobial 
Stewardship Network teams and in the Virtual Critical Care Units.  
Students received daily alerts for any POC blood glucose check that was > 179 or < 70 for a patient in 
Med 1 (User Protocol in appendix). Each morning, students received alerts for patients who had POC 
blood glucose readings that were outside the acceptable range. The TheraDoc software allows the user 
to analyze labs and trends as well as medications. In addition to the alert, students used charting for the 
patient to assess for potential therapeutic modifications. Students could then propose an intervention if 
an intervention was necessary. The initial proposal was given to the pharmacy preceptor, and then to 
the physician, in person or over the phone. Student interventions could be cataloged according to two 
dimensions of the proposal; the first was related to administration and dose and the second was related 
to the type of insulin. The type of insulin that could be adjusted was either “basal,” “bolus,” or 
“correction.” Doses could be “initiated,” “modified,” or “reduced.” Any combination of the two 
dimensions was allowed, for example “initiate basal insulin” or “modify correction insulin.” Following 
the proposal to the physician, the result was logged as either “accepted,” “accepted – modified,” or 
“rejected,” depending on the result. Patient medications were allowed to be modified on multiple 
occasions, for example, a proposal could be made to “initiate bolus insulin” one day and then “reduce 
(modify) sliding scale insulin” the next day.  
                                                      
Figure 1: Possible intervention options. Students propose an intervention to initiate, modify or discontinue any component of a patient’s insulin 
regimen. “Modify” could include increases or reductions. 
No students were on rotation in August 2016 since the pharmacy residents were going through training 
during that month. The second intervention was initiated from August and going forward indefinitely. 
Interdisciplinary rounds were restructured in Med 1, Med 2 and Med 3 to include a clinical pharmacist 
plus a 4th year pharmacy student and/or a pharmacy resident. Pharmacy representation in 
interdisciplinary rounds covered a variety of therapeutic monitoring including drug interactions, 
anticoagulation, antimicrobials, IV to PO conversion, renal dosing adjustments, and glycemic control 
among other things. Proposals could be made during interdisciplinary rounds which included providers, 
nurses, social workers, diabetes educators and pharmacy. They did not use TheraDoc during this phase, 
but instead worked up each patient individually. These rounds have been ongoing since this initial 
phase. 
Out-of-range POC readings during all months of the HEN 2.0 period were excluded within the first 24 
hours of hospital admission, and within 2 hours of another alert. The rationale for this was to give 
providers time to correct dysglycemia from prior to admission, and to reduce the impact of repeated 
measurements during a period of intense dysglycemia from skewing the data. The same criteria were 
used for the baseline data.  
 
Results 
Data from the baseline period of November 2015 to January 2016 were used to target interventions that 
might lead to the greatest effect. The data were broken down by a variety of characteristics, including 
provider group, hospital unit, patient demographics, and others. There were a total of 12,742 out-of-
range readings during the baseline months. This number came from 1,288 different patients. Within 
those patients with readings > 179mg/dL, the top 10% of patients made up 40% of the readings. A large 
number of patients (29% of the group) had only 1 or 2 high readings. Approximately 93% of all of the 
out-of-ranger POC were due to hyperglycemia. The hospital unit with the highest percentage of out-of-
range readings was the med units Med1-Med3 (Table 1). Most of the other hospital units had a fairly 
even distribution of out-of-range readings, accounting for between 4-8%. The provider group with the 
highest percentage of readings coming from patients under their care was Carolinas Hospitalist Group 
(Table 2). Approximately 50% of the readings came from CHG patients. 
 
 
 
 
 
 
 
 
 
Table 1: Percentage of Out-of-range Readings by Unit Table 2: Percentage of Out-of-range Readings by Provider Group 
 
 
Med Units: General Medical/Surgical Units; IPU: InterPulmonary Unit; 
PCCU: Cardiac Care Unit; CIE: Cardiac Unit; PSC: Post-surgical Care Unit; 
RSE: Renal/Dialysis Unit; CDE/FME: Family Medicine/Clinical Decision 
Units; ONE: Oncology 
CHG: Carolinas Hospitalist Group; CFM: Cabarrus Family Medicine 
 
Due to a variety of factors, including the small number of patients in each unit, there was considerable 
variability from one month to the next. With regard to the raw percent of out-of-range numbers for the 
three time frames, there does seem to be a downward trend in the percentage of out-of-range readings. 
In the pre-interventional phase of January through April, the average out of range readings was 57%. 
During the student phase of May through July, the average was 53%, and during the interdisciplinary 
rounds phase of August-December the average was 35%. There is certainly a steady trend toward a 
decline in hyperglycemia over the course of the year (Figure 2, Table 3). 
 
 
Figure 2: Percentage of hyperglycemic readings for Med 1 only (green line) and Med 1-3 combined (blue line). Dashed lines represent overall 
trends for the year. 
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> 179 
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M1-3% 
> 179 
42 55 50 50 48 48 44 35 40 29 26 31 
Table 3: Numerical representation of percentage of hyperglycemic readings 
 
During HEN 1.0 there had been considerable progress at CHS NorthEast with regard to incidents of 
hypoglycemia. A major concern with all of the stakeholders was than any reduction in incidents of 
hyperglycemia would not increase the incidents of hypoglycemia. The trend for hypoglycemia roughly 
follows that of hyperglycemia, with variation throughout the year, but an overall reduction from start to 
finish in both Med 1 and all of the med units (Figure 3).  
 
 
Figure 3: Percentage of hypoglycemic readings for Med 1 only (green line) and Med 1-3 combined (blue line). Dashed lines represent overall 
trends for the year. 
 
Students initiated 114 total interventions, 20 of which were accepted and implemented. The majority of 
accepted interventions were to initiate bolus insulin, followed by initiating basal insulin (Figure 4). A 
large number of potential interventions were never implemented either due to actual patient 
discharges, or potential patient discharges that did not happen until a later date. Other factors that 
accounted for interventions that were not accepted included patient transfers to other units and 
dysglycemia that was corrected prior to intervention. 
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 Figure 4: Types of accepted student intervention by percent 
 
Discussion 
The decision to target Med 1 for intervention was due to a variety of factors. Looking at the baseline 
data it was clear that the areas with the highest percentage of out-of-range readings were the med 
units, and patients under the care of CHG physicians. With limited time and resources, any intervention 
would have to be targeted for the greatest return on investment. The decision to try interdisciplinary 
rounds came partly out of the observation of outstanding glycemic control in the ICU. Despite having the 
sickest patients in the hospital, the ICU accounts for a disproportionally small percentage of the elevated 
POC glucose readings. This may be due to the fact that the ICU has well-established, meaningful 
interdisciplinary rounds in place that serve to control a number of potential problems, including 
dysglycemia. 
Overall, the trend was toward improvement of glycemic control over the intervention period and 
beyond. The goal of a 40% overall reduction was not achieved during the HEN 2.0 timeframe, and has 
still not been achieved, although percentages in recent months are approaching the 22% mark.  
At the beginning of the project there was strong support among some providers for using sliding scale 
insulin as the primary therapy for most of the patients. There were several reasons expressed for this. 
One was that many patients have a brief stay in the hospital, or transfer units rapidly. The idea is that 
using sliding scale can keep blood sugars from getting too high while they are admitted, and then the 
patient can go back on their home regimen. The main concern was that using the full hospital protocol 
as written could lead to overdoses of insulin and hypoglycemia. During a previous improvement grant, 
HEN 1.0, the focus had been on reducing incidents of hypoglycemia in particular. The staff at NorthEast 
was very successful with this goal, reducing the overall rate of hypoglycemia to 2.1%.  Even though this 
was a positive goal, it may have contributed to a conservative approach to hyperglycemia in order to 
avoid hypoglycemia. It is possible to reduce hyperglycemia without significantly increasing 
hypoglycemia, and efforts should be med to reduce both.  Indeed, during the study period there was 
actually a reduction in the rate of hypoglycemia, even though the rate of hyperglycemia improved 
dramatically. Providers became more comfortable with initiating at least basal and correction insulin, as 
well as prandial insulin as well in many patients.  
There were several limitations of this particular study. The most important were probably the limited 
timeframes for the interventions, and the small size of the interventions. The student TheraDoc period 
was especially short in duration and only involved a 15 bed unit. There is considerable variability in 
glycemic control, even prior to the initiation of the intervention. Unfortunately factors such as student 
schedules and workload limited the scope of this intervention. Students were only on rotation for a 
month at a time, and only from 07:00 to 15:00 M-F, so were only able to make interventions during that 
time. Four different students participated in the study and there were differences in number of 
interventions made by each student. During the study period, NorthEast did not assign physicians to 
particular units, which made interventions difficult on a practical level. In the past few months the 
hospital has made the decision to transition to having physicians cover specific units, which increases 
the likelihood of making an in-person recommendation, particularly at rounds.  
Despite the limitations, blood glucose readings appear to be under much better control. This has taken 
place within a fairly short period of time. The interdisciplinary rounds seem to have had the largest, and 
most sustained effect. The students who used the TheraDoc alerts did find them to be useful for 
targeting specific interventions. The software is easier to use that the hospital charting system Cerner 
and students were able to identify and formulate interventions quickly. A possible future strategy would 
be to combine both interventions, that is to use TheraDoc alerts for interdisciplinary rounds. This could 
be used not only for glycemic control, but also for the other things that are monitored such as 
antimicrobials, anticoagulation and various laboratory parameters. With the help of pharmacy 
extenders, such as APPE students, this could become a regular addition to the pharmacy service. A 
major limitation of either intervention is the inability to scale up to cover the whole hospital. A little 
more than 50% of the beds in the hospital are covered by pharmacy representation at interdisciplinary 
rounds. Increasing this number would likely require more students, residents, and/or increased 
pharmacy FTE. 
There are countless variables that affect glycemic control in the hospital. This project was limited by a 
quick development phase, a short overall duration, and a limited group of patients receiving the 
intervention. With all of that taken into account, the results from the med units, particularly since the 
initiation of interdisciplinary rounds is impressive. Adding more targeted pharmacy oversite to glycemic 
control can be beneficial with regard to several outcomes, including length of stay, patient health, and 
cost to the patient and healthcare system. Utilization of pharmacy extenders and surveillance software 
are potential options for increasing the reach of pharmacy into patient care. 
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